Previous 10 | Next 10 |
ChemoCentryx (CCXI) has gained ~2.2% in the premarket after announcing that The New England Journal of Medicine has published the Phase 3 data from the ADVOCATE trial.The pivotal, randomized, double-blind, active-controlled, double-dummy study evaluated the orally-administ...
-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan’s effects on kidney function, patient Quality of Life, and reduction in overall...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with this event. For further details see: ChemoCentryx (CCXI) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
CCXI has a very successful trial of CCX168 in ANCA-AAV, and mixed data in other indications. I believe CCX168 will be easily approved in ANCA-AAV; but I have mixed feelings about the rest of the pipeline. Given that, I will wait for a better entry point. For further details ...
MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Comm...
ChemoCentryx (CCXI) down 5% after hours on topline data from Phase 2 study, ACCOLADE, evaluating avacopan for the treatment of C3 glomerulopathy (kidneys malfunction leading to excess levels of protein in urine).The trial showed the change from baseline to week 26 in C3 glomeru...
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
ChemoCentryx, Inc. (CCXI) Q3 2020 Earnings Conference Call November 09, 2020 05:00 PM ET Company Participants Steve Klass - Investor Relations, Burns McClellan Thomas Schall - Chairman, President and Chief Executive Officer Susan Kanaya - Executive Vice President, Chief Financial and Administ...
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q3 2020 Earnings Call Nov 9, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...